No headlines found.
No press releases found.
No news found.
The Fund will invest primarily in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies (Healthcare Companies) which the adviser believes are leaders and where the magnitude and/or duration of future growth for these companies is underappreciated by the market. The Fund will invest in common stocks of Healthcare Companies across all market capitalizations, but expects to invest a majority of its assets in mid- and large- capitalization companies. The Fund will invest globally, including in both developed and emerging market countries, although it expects to invest a majority of its Assets in Healthcare Companies located in the U.S.
JPMorgan Healthcare Leaders ETF trades on the NASDAQ stock market under the symbol JDOC.
As of April 23, 2026, JDOC stock price declined to $55.53 with 315 million shares trading.
JDOC has a market cap of $11.11 million. This is considered a Sub-Micro Cap stock.
JDOC has underperformed the market in the last year with a price return of +12.9% while the SPY ETF gained +35.8%. JDOC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -6.9% and -1.9%, respectively, while the SPY returned +3.1% and +4.8%, respectively.
JDOC support price is $55.38 and resistance is $56.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JDOC shares will trade within this expected range on the day.
